The application of Uro-vaxom®, urinary tract immunostimulator in the treatment of chronic pelvic pain syndrome

Abstract

Purpose: There are a variety of techniques for treating chronic prostatitis. Regardless of the presence of infections, antibiotics were arbitrarily prescribed for 4-12 weeks, but there seemed to be ongoing debate of their effectiveness and side effects. Uro-vaxom® is known as an effective treatment for urinary tract infection due to its initiation the urothelial immune system activity. This study was performed to investigate for the possibility of Uro-vaxom® as a drug for use in non-inflammatory chronic prostatitis. Materials and methods: 95 patients, diagnosed as chronic pelvic pain syndrome (CPPS) (National Institutes of Health (NIH)-category IIIB), were divided into three groups: group A, 35 patients were given levofloxacin 100mg TID and Uro-vaxom® 60mg OD for the first 4 weeks, followed by only Uro-vaxom® 60mg OD for the next 8 weeks; group B, 30 patients were given only Uro-vaxom® 60mg OD before breakfast for 12 weeks; group C, the patients were treated with levofloxacin 100mg TID for 4 weeks. All the patients were reevaluated 4 weeks and 12 weeks later. Results: The initial diagnostic stati, the NIH-Chronic Prostatitis Symptom Index (CPSI) were 25.1±2.7, 24.4±3.2 and 24.7±2.2 for groups A, B and C, respectively. In groups A and B, the NIH-CPSI after 12 weeks were 13.5±2.3 and 13.9±2.7, respectively, and showed noticeable improvements (p<0.05). In group C, the NIH-CPSI was 15.7±3.4, which was less improved compared to groups A and B (p>0.05). No patients experienced any adverse symptoms due to Uro- vaxom® intake. Conclusions: Uro-vaxom® could be appointed as an alternative method for the treatment of chronic prostatitis.